Over 30 years of experience in genomics
Since 1992, Cerba Research and Cerba Healthcare have pioneered the art of human genetic testing, as we were the first laboratory in Europe to introduce genetic testing.
Thanks to this experience, we are able to collaborate with the life science community to provide the most suitable genomic services and enhance the power of your genetic material.
Cerba Research can work with you to select the most suitable platform and assay to reach your project expectations.
Our Genomics Solutions
Next Generation Sequencing Capabilities
Cerba Research is able to propose fit-for-purpose Next Generation Sequencing capabilities, by means of numerous comprehensive broad panel assays available for analysis, and more.
Next Generation Sequencing For Solid Tumors
Our experienced scientific team provides a flexible, customizable and responsive approach to your NGS solid tumor clinical trials.
Next Generation Sequencing For Hematological Malignancies
Cerba Research offers state-of-the-art genomic technologies to obtain the essential dataset of your samples dedicated to hematological malignancies.
Next Generation Sequencing For Liquid Biopsies
Cerba Research is proud to be at the forefront of cancer early detection thanks to our liquid biopsies (ctDNA) NGS solutions.
Genomic For Infectious Diseases
Cerba Research can support your infectious disease trial with our genomic capabilities.
Constitutional Genomic
We are happy to propose whole exome/genome sequencing including SNP, CNV and indel.
Custom Assay Development
We are able to provide custom laboratory assay, panel design and medical grade reports.
Immune Repertoire Sequencing
Cerba Research powers up with its partner ENPICOM to provide tailored, End to End solutions to its customers in decoding immune repertoire.
55
7
25 000
Our Genomics Landscape
Discover the diversity of our genomics platform, tailored for your project
● Single nucleotide variants (SNV)
● Insertion and deletions (numerous broad panel assays aligned with guidelines)
● Copy number variations (CNV)
● Gene fusions
● Tumor mutational burden (TMB)
● Microsatellite instability (MSI)
● Minimal residual disease (MRD) on demand
● Homologous recombination deficiency (HRD)
● Somatic hypermutation
Cerba Research’s family of qPCR solutions is designed to simplify your process and expedite your clinical trial results and to help you answer important clinical questions faster and easier. For example, we can detect EGFR alterations by means of FFPE and ctDNA using qPCR instruments.
Cerba Research also owns droplet digital (ddPCR) instruments. ddPCR is a method that can perform digital PCR which is based on water-oil emulsion droplet technique. ddPCR may also offer a robust mutation detection sensitivity (0.05-0.1%).
Analyses of miRNA are carried out with protocols similar to those utilized for protein-encoding genes. The artificial up-regulation of miRNAs can aid in identifying gain-of-function phenotypes, and the down-regulation can be carried out to determine loss-of-function phenotypes. Combining both up- and down-regulation can help identify cellular processes and genes that are controlled by specific miRNAs.
The TCR repertoire, that is, the diverse collection of clonotypes in an organism, plays an important role in shaping the immune function, health, and disease progression. At Cerba Research, we are able to perform TCR seq by means of NGS with various already existing and validated kits.
Nanostring is an amplification-free technology that measures nucleic acid content by counting molecules directly. It enables researchers to analyze and interpret differential gene expression results and benefit from a solution for multiplex analysis of 800+ targets.
Cerba Research is proud to propose whole exome and whole genome sequencing capabilities, including coding, non-coding and mitochondrial DNA.
We can also help you discover novel genomic variants (structural, single nucleotide, insertion-deletion, copy number) and previously unknown variants identification for future targeted studies.
Finally, we can guide you through your whole exome sequencing journey with 22,000 genes and clinical exome sequencing capabilities with 6,000 genes, including SNPs, CNVs, and indels.
BCR sequencing explores the diversity of the B-cell receptor repertoire through sequencing. Cerba Research is committed to providing comprehensive solutions with the best quality to advance your global cell therapy trial. We already have experience with already existing and validated kits for your BCR sequencing needs.
Analysis of the genes coding for the 16S ribosomal RNA for bacterial identification and the ITS region for the characterization of fungal species.
- Genotyping (Massarray)
• CGH array
• HLA Typing
• PGx
• And more…
Discover the Benefits of Our Genomics Services
Reach out to our experts and see how we can help advance your research